Page 1

ROQUEFORT INVESTMENTS PLC Roquefort Investments plc ( " Roquefort Investments " or the " Company " ) Interim Results to 30 June 2021 Roquefort Investments plc ( LSE : ROQ ) , the London listed investment company established to acquire businesses focused on early - stage opportunities in the medical biotechnology sector , is pleased to present its interim results for the six - month period ended 30 June 2021 . Highlights · • Successfully admitted to trading on the London Stock Exchange ( " LSE " ) as of 22 March 2021 Cash Balance at period end of £ 880,445 Chairman Statement I am pleased to present the interim financial statements to shareholders for the six months ending 30 June 2021 . During the period under review the Company was primarily concerned with listing on the standard segment of the London Stock Exchange , which was successfully achieved on 22 March 2021. The Company then turned its attention to identifying and screening suitable businesses focused on early - stage opportunities in the medical biotechnology sector . Post period end , on 29 September 2021 we were delighted to announce that Roquefort Investments had entered into non - binding term sheet ( " Term Sheet " ) with Provelmare Holding S.A. to acquire 100 % of the total issued equity in Lyramid Limited ( " Lyramid " ) for an initial consideration of £ 1 million payable 50 % in cash and 50 % in shares ( the " Transaction " ) . Lyramid has the exclusive worldwide licence to commercialise up to 37 patents related to Midkine- based therapies for the treatment of COVID - 19 patients , cancer , autoimmune disorders and chronic kidney disease ( " Midkine - Based Therapies " ) . The Directors of Roquefort Investments consider the Transaction to represent a transformational , value enhancing transaction for shareholders , which is fully aligned with the Company's growth strategy . Lyramid's global patent portfolio for Midkine - Based Therapies provides a platform to develop first - in - class drugs for the treatment of severe inflammatory diseases , autoimmune disorders and cancer . The therapeutic potential of Midkine - Based Therapies has been validated during more than 10 years of research including collaborations with leading academic centres and clinicians resulting in over 900 scientific publications . To fund the Transaction , Roquefort Investments will be seeking to carry out a placing of new ordinary shares to new and existing investors ( " Placing " ) to raise funds of up to £ 3 million to finance the cash component of the consideration , pre - clinical drug development and working capital . As such , the Transaction is conditional , inter alia , on a successful Placing . Should the Transaction complete , it would constitute a Reverse Take - Over ( " RTO " ) under the Listing Rules and accordingly the Company would apply for the re - admission of its shares to the Official List and the Main Market of the London Stock Exchange . Where an RTO is contemplated but has not yet been completed , the FCA will normally suspend a company's listing pending the publication of a prospectus prepared in accordance with the prospectus regulation rules of the FCA and approved by the FCA , or an announcement that the Transaction is not proceeding . Therefore , at the request of the Company , the FCA suspended the Company's listing on the standard segment of the Official List as of 29 September 2021. Trading on the Main Market of the London Stock Exchange has also been suspended as of 29 September 2021 . I look forward to reporting our progress on this potentially transformative transaction to you in the coming weeks and thank all shareholders for their continued support .